Cao Ting-ting, Chen Jun-tao, Yang Chun-liu, Tian Yun-feng, Feng Teng-lei, Ma Zheng-yue
Yao Xue Xue Bao. 2016 Sep;51(9):1436-40.
Alzheimer’s disease (AD) is a degenerative disease of the nervous system. Compound I reported to have inhibitory activity on AChE was used as a lead compound in this study, and 4-pyridinylthiazole-2-amines were designed by optimizing compound I structure. The new compounds were synthesized from acetylpyridines through five-steps of reaction, and their inhibition activities on AChE were measured in vitro by Ellman method. The new compounds exhibited a clear inhibitory activity on AChE in vitro. The bioactivity of compound 13c was the best among them, and its IC(50) value was 0.15 μmol·L(-1), which was better than that of rivastigmine and compound I in the control. Meanwhile, it exhibited little inhibition on butyrylcholinesterase. So the selective inhibitory activities of 4-pyridinylthiazole-2-amines to acetylcholinesterase were worth of studying furtherly.
阿尔茨海默病(AD)是一种神经系统退行性疾病。本研究中,将据报道对乙酰胆碱酯酶(AChE)具有抑制活性的化合物I用作先导化合物,并通过优化化合物I的结构设计了4-吡啶基噻唑-2-胺。新化合物由乙酰吡啶经五步反应合成,并采用Ellman法在体外测定其对AChE的抑制活性。新化合物在体外对AChE表现出明显的抑制活性。其中化合物13c的生物活性最佳,其IC50值为0.15 μmol·L-1,优于对照中的利伐斯的明和化合物I。同时,它对丁酰胆碱酯酶的抑制作用很小。因此,4-吡啶基噻唑-2-胺对乙酰胆碱酯酶的选择性抑制活性值得进一步研究。